
Sivapalaratnam
@sivapalaratnam
Academic Consultant
ID: 94988620
06-12-2009 12:17:51
79 Tweet
94 Followers
189 Following

Thank you Professor Beverley Hunt OBE (also on BlueSky) & Roopen Arya raising awareness of #thrombosis in #COVID19 on BBC Breakfast bbc.co.uk/news/health-52…

It’s like the Wild West out there with lots of different protocols,” says Roopen Arya. Well said! We need #RCTs. Professor Beverley Hunt OBE (also on BlueSky) Michelle Sholzberg INVENT-VTE Covid-19 and thrombosis: what do we know about the risks and treatment? | The BMJ bmj.com/content/369/bm…

Indeed excellent BBC News (UK) reporting on clots in #COVID-19. Also pointing out the challenge of #RCTs and ‘priorisation’ of research in the UK. The unprioritised #anticoagulant trial still laying on a shelf for many weeks now... Professor Beverley Hunt OBE (also on BlueSky) Marcel levi Dan Hart





also including Suthesh Sivapalaratnam Sivapalaratnam from Barts Health NHS Trust 👏


Goedemorgen! Toch even delen: van de opgenomen #COVID19 patiënten tijdens mijn dienst #internegeneeskunde Radboudumc, was niemand gevaccineerd. We moeten blijven #vaccineren en uitleggen hoe belangrijk dat is. #haaldieprik!

Here’s a photo for your opening slides for all you haemophilia teachers out there . Arguably the most famous person to ever have lived with haemophilia (sorry Alex Dowsett & Chris Bombardier, MS in Global Health) on his final journey to Yaketerinburg where he and family were assassinated.

Great to have Haemophilia Society join us @RoyalLondonHosp Barts Health to raise awareness about inherited and acquired bleeding 🩸 disorders for delayed WFH world haemophilia day advocacy


Results from the Highlow RCT presented by Saskia Middeldorp at #ISTH2022 comparing intermediate vs low dose LMWH in pregnant women who have had previous VTE. Antenatal no difference between dose for VTE, postpartum intermediate dose may be more protective.


Delighted to announce a Clinical Trial Authorization (CTA) clearance by UK MHRA (Medicines and Healthcare products Regulatory Agency) for VERVE-101 as investigational Rx for patients with heterozygous familial hypercholesterolemia ir.vervetx.com/news-releases/… $VERV Verve Therapeutics



Sivapalaratnam, Account no longer active, AlanMitchell & I present to y'all 32 genes from the ThromboGenomics diagnostic-grade assay that are also significantly DE in platelets from MPN patients: we hope this candidate gene set helps spur(& prioritize) further mechanistic & outcome studies!👇

Great first talk of #EAHAD2024 “high energy” SLAM session of EAHAD by Sivapalaratnam on #Glanzmann #thrombasthenia with early results of Hemab Therapeutics study of HMB-001 antibody #bleedingdisorders


Find out more: bartslifesciences.org/using-data-to-… Sivapalaratnam

Early meeting at #ISTH2024 in #bangok to plan for the 2025 Congress in Washington! With lovely colleagues Annette Bowyer and Sivapalaratnam and 🌟view! ALREADY ? YES this is how organized our ISTH is. Check out membership benefits and join us now! isth.org/page/Membershi…


Great opportunity to work with the Haem-Match and BloodCounts! team UCLH NIHR UCLH Biomedical Research Centre to improve the care of those with #sickle #thalassaemia using #data, #Bioinformatics #statistics uclh.nhs.uk/work-with-us/c…